Investments
65Portfolio Exits
6Partners & Customers
1
Want to inform investors similar to Leaps by Bayer about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Research containing Leaps by Bayer
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Leaps by Bayer in 1 CB Insights research brief, most recently on Aug 8, 2023.
Latest Leaps by Bayer News
Sep 20, 2023
September 20, 2023 ReCode Therapeutics , a Menlo Park, CA-based clinical-stage genetic medicines company using precision delivery mRNA and gene correction therapeutics, closed an extension to its Series B financing, raising an additional $50m, for a total of $260m. Backers included new backers Bioluminescence Ventures and Solasta Ventures, and existing investors including OrbiMed Advisors, AyurMaya, an affiliate of Matrix Capital Management, Leaps by Bayer, Vida Ventures, MPM Capital, Pfizer Ventures, EcoR1 Capital, Sanofi Ventures and Amgen Ventures, Osage University Partners (OUP), among others. Kouki Harasaki, Ph.D., founding and managing partner of Bioluminescence Ventures (BLV), joined the company’s board of directors. The company intends to use the funds to advance its primary ciliary dyskinesia and cystic fibrosis clinical development programs and to expand its proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) pipeline to include mRNA and gene correction therapeutics for central nervous system, lung, liver and musculoskeletal indications. Led by Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer, ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power mRNA and gene correction therapeutics. Its Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables precise and targeted delivery of genetic medicines directly to the organs and cells implicated in disease, enabling improved efficacy and potency. Its lead programs include RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene, and RCT2100 for the treatment of the 10-13 percent of cystic fibrosis patients who have Class I mutations in the CFTR gene and do not respond to currently approved CFTR modulators. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated using the SORT LNP delivery platform. ReCode is expanding its pipeline to develop potential therapies for other rare and common genetic diseases including musculoskeletal, central nervous system, liver and infectious disease indications.
Leaps by Bayer Investments
65 Investments
Leaps by Bayer has made 65 investments. Their latest investment was in Mozart Therapeutics as part of their Series A - II on June 6, 2023.

Leaps by Bayer Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
6/7/2023 | Series A - II | Mozart Therapeutics | $25M | No | 8 | |
5/16/2023 | Series C | Boundless Bio | $100M | Yes | Alexandria Venture Investments, ARCH Venture Partners, City Hill Ventures, Fidelity Investments, GT Healthcare Capital Partners, Leaps by Bayer, Logos Capital, Nextech Invest, PFM Health Sciences, Piper Heartland Healthcare Capital, RA Capital Management, Redmile Group, Sectoral Asset Management, Surveyor Capital, Vertex Ventures HC, and Wellington Management | 8 |
5/10/2023 | Series A | ChrysaLabs | $11M | Yes | Anges Quebec, AQC Capital, BDC Capital, Ecofuel Accelerator, Emmertech, Koan Capital, Leaps by Bayer, and TELUS Ventures | 4 |
3/19/2023 | Series B | |||||
2/27/2023 | Series A |
Date | 6/7/2023 | 5/16/2023 | 5/10/2023 | 3/19/2023 | 2/27/2023 |
---|---|---|---|---|---|
Round | Series A - II | Series C | Series A | Series B | Series A |
Company | Mozart Therapeutics | Boundless Bio | ChrysaLabs | ||
Amount | $25M | $100M | $11M | ||
New? | No | Yes | Yes | ||
Co-Investors | Alexandria Venture Investments, ARCH Venture Partners, City Hill Ventures, Fidelity Investments, GT Healthcare Capital Partners, Leaps by Bayer, Logos Capital, Nextech Invest, PFM Health Sciences, Piper Heartland Healthcare Capital, RA Capital Management, Redmile Group, Sectoral Asset Management, Surveyor Capital, Vertex Ventures HC, and Wellington Management | Anges Quebec, AQC Capital, BDC Capital, Ecofuel Accelerator, Emmertech, Koan Capital, Leaps by Bayer, and TELUS Ventures | |||
Sources | 8 | 8 | 4 |
Leaps by Bayer Portfolio Exits
6 Portfolio Exits
Leaps by Bayer has 6 portfolio exits. Their latest portfolio exit was Azitra on June 16, 2023.
Leaps by Bayer Partners & Customers
1 Partners and customers
Leaps by Bayer has 1 strategic partners and customers. Leaps by Bayer recently partnered with Temasek on August 8, 2020.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
8/12/2020 | Partner | Singapore | Bayer and Temasek team up to develop vegetable varieties for vertical farming Unfold raised USD 30 million in the initial funding round and entered into an agreement for certain rights to germplasm from Bayer AG 's vegetable portfolio . | 2 |
Date | 8/12/2020 |
---|---|
Type | Partner |
Business Partner | |
Country | Singapore |
News Snippet | Bayer and Temasek team up to develop vegetable varieties for vertical farming Unfold raised USD 30 million in the initial funding round and entered into an agreement for certain rights to germplasm from Bayer AG 's vegetable portfolio . |
Sources | 2 |
Leaps by Bayer Team
8 Team Members
Leaps by Bayer has 8 team members, including current Executive Vice President, Jürgen Eckhardt.
Name | Work History | Title | Status |
---|---|---|---|
Jürgen Eckhardt | Executive Vice President | Current | |
Name | Jürgen Eckhardt | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Executive Vice President | ||||
Status | Current |